Last update 20 Mar 2025

Vatiquinone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Vatiquinone (JAN/USAN), Vincerenone
+ [2]
Target
Action
inhibitors
Mechanism
12/15-LOX inhibitors(Arachidonate 15-lipoxygenase inhibitors)
Originator Organization
Active Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationOrphan Drug (Japan), Rare Pediatric Disease (United States), Fast Track (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H44O3
InChIKeyLNOVHERIIMJMDG-XZXLULOTSA-N
CAS Registry1213269-98-7

External Link

KEGGWikiATCDrug Bank
D10407--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Friedreich AtaxiaNDA/BLA
United States
19 Feb 2025
Diffuse Cerebral Sclerosis of SchilderDiscovery
Canada
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
Japan
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
United Kingdom
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
Spain
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
France
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
Sweden
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
United States
28 Sep 2020
Diffuse Cerebral Sclerosis of SchilderDiscovery
Poland
28 Sep 2020
Leigh DiseaseDiscovery
Japan
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
20
Placebo+EPI-743
(EPI-743, Then Placebo)
lfdyorbrmc(hoyhzywloj) = pjcttyhkeu ochicsxpnb (ovrrexmmwq, ehbhwzyksg - mpedjtspnv)
-
14 Apr 2021
Placebo+EPI-743
(Placebo, Then EPI-743)
lfdyorbrmc(hoyhzywloj) = jdqtjdjpze ochicsxpnb (ovrrexmmwq, qdvvwuqhcp - vuvuwikgpl)
Not Applicable
3
(koikehwjtk) = No serious adverse events, including hematologic or cardiac, were observed kzomrzqwmo (hwfdrhihbe )
Positive
05 Apr 2016
Phase 2
-
10
vlkjaeqkso(yprummltfu) = pjhdzgjbww ksbarkbnww (rxjbrkfgqg )
Positive
05 Apr 2016
vlkjaeqkso(yprummltfu) = fugrytktqi ksbarkbnww (rxjbrkfgqg )
Phase 2
glutamine/glutamate levels
10
uvonsimtqz(srgyappdog) = nmhaxaxgab swixnyihfc (utsssvuadp )
Positive
05 Apr 2016
uvonsimtqz(srgyappdog) = kpqqpplrkm swixnyihfc (utsssvuadp )
Not Applicable
Optic Atrophy, Hereditary, Leber
Neuron specific enolase (NSE)
12
LHON patients receiving EPI-743
cwwkveevlg(efoslzuffj) = ymnkdtjksf jfkdholddd (bspueodlge, 6.21 - 12.64)
Positive
01 Jun 2013
(Normal controls)
cwwkveevlg(efoslzuffj) = gqtxzujhxl jfkdholddd (bspueodlge )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free